Inflammation and breast cancer. Inflammatory component of mammary carcinogenesis in ErbB2 transgenic mice.
This review addresses genes differentially expressed in the mammary gland transcriptome during the progression of mammary carcinogenesis in BALB/c mice that are transgenic for the rat neu (ERBB2, or HER-2/neu) oncogene (BALB-neuT664V-E mice). The Ingenuity knowledge database was used to characterize four functional association networks whose hub genes are directly linked to inflammation (specifically, the genes encoding IL-1beta, tumour necrosis factor, interferon-gamma, and monocyte chemoattractant protein-1/CC chemokine ligand-2) and are increasingly expressed during such progression. In silico meta-analysis in a human breast cancer dataset suggests that proinflammatory activation in the mammary glands of these mice reflects a general pattern of human breast cancer.
Calogero
Raffaele Adolfo
RA
Molecular Biotechnology Center, Department of Clinical and Biological Sciences, Via Nizza 52, 10126 Turin, Italy.
Cordero
Francesca
F
Forni
Guido
G
Cavallo
Federica
F
D000818:Animals; D002471:Cell Transformation, Neoplastic / Q000276:immunology*; D018734:Genes, erbB-2 / Q000276:immunology*; D007249:Inflammation; D008321:Mammary Glands, Animal / Q000276:immunology*; D015674:Mammary Neoplasms, Animal / Q000235:genetics / Q000276:immunology / Q000473:pathology; D051379:Mice; D008822:Mice, Transgenic
J Clin Invest. 2004 Mar;113(5):709-17
14991069
Cancer Res. 2001 Apr 15;61(8):3518-23
11309316
J Exp Med. 1998 Aug 3;188(3):589-96
9687535
Bioinformatics. 2004 Dec 12;20(18):3705-6
15297296
Am J Pathol. 2005 Apr;166(4):1205-16
15793299
Cancer Cell. 2006 Dec;10(6):529-41
17157792
BMC Bioinformatics. 2005;6 Suppl 4:S7
16351756
Nat New Biol. 1971 May 12;231(19):53-4
5283388
J Immunol. 1990 Nov 1;145(9):3136-43
2212677
Nat Med. 2003 Jul;9(7):831-5
12835699
Br J Cancer. 1994 Mar;69(3):572-6
8123489
Nat Rev Cancer. 2007 Jan;7(1):23-34
17167517
Nucleic Acids Res. 2007 Jan;35(Database issue):D26-31
17148475
Stat Med. 1998 Sep 30;17(18):2107-19
9789917
J Immunol. 1985 Feb;134(2):1305-11
3871210
J Clin Oncol. 1999 Jul;17(7):2105-16
10561265
J Natl Cancer Inst. 1997 Jul 16;89(14):1049-58
9230887
J Immunol. 2000 Mar 15;164(6):3200-6
10706711
J Pathol. 1998 Dec;186(4):390-7
10209488
Novartis Found Symp. 2004;256:29-41; discussion 41-52, 266-9
15027482
Cancer Res. 2004 Apr 15;64(8):2858-64
15087404
Cancer Res. 2001 Apr 1;61(7):2809-12
11306448
Stat Appl Genet Mol Biol. 2004;3:Article3
16646809
Nat Rev Immunol. 2005 Oct;5(10):749-59
16175180
Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37
11252954
Cancer Cell. 2006 Dec;10(6):515-27
17157791
Breast Dis. 2004;20:33-42
15687705
J Immunol. 1992 Dec 1;149(11):3627-35
1358974
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2645-50
12598651
Cancer Immunol Immunother. 2005 Jun;54(6):599-610
15690207
Clin Cancer Res. 2004 May 1;10(9):2922-7
15131026
Clin Cancer Res. 2005 Mar 1;11(5):1941-52
15756020
Nat Med. 1999 Jul;5(7):828-31
10395330
J Immunol. 2006 Dec 1;177(11):7626-33
17114432
Blood. 2003 Sep 15;102(6):2138-45
12750171
Cancer Res. 1994 Dec 1;54(23):6022-6
7954438
Cancer Res. 2006 Aug 1;66(15):7734-40
16885376
J Immunol. 1994 Nov 15;153(10):4604-15
7963533
Cancer Immun. 2006;6:6
16551058
Adv Exp Med Biol. 1990;267:483-500
2088067
Immunol Today. 1997 Jan;18(1):32-6
9018972